Spain hits 100 — OncoSil Medical reaches commercial milestone in key European market
OncoSil Medical (ASX: OSL) has announced that the 100th patient in Spain has been treated with its OncoSil™ device, marking a significant milestone in the company’s continued commercial expansion in the country. The milestone procedure was performed at Hospital HM Sanchinarro, Madrid on 7 September 2026.
The achievement reflects ongoing clinical adoption across an established network rather than a first-ever event. With 11 active treatment sites now operational across Spain, the milestone underscores growing engagement from Spanish clinicians and hospitals with the OncoSil™ treatment for unresectable locally advanced pancreatic cancer (LAPC).
When big ASX news breaks, our subscribers know first
Why Spain matters to OncoSil’s European strategy
Spain occupies a meaningful position within OncoSil Medical’s broader European commercialisation strategy, driven by a substantial patient population and an expanding hospital network.
Key Spain-specific facts from the announcement include:
- Approximately 9,200 new pancreatic cancer cases diagnosed in Spain annually
- 11 active treatment sites currently operational across the country
- Spain described by the company as one of its “key European markets”
- Commercial treatments have already been undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel, and the UK
- OncoSil™ holds CE Marking approval, providing marketing authorisation across the European Union and the United Kingdom, and is approved for sale in 30+ countries
It is worth noting that the announcement describes Spain as “an important” European market, not the primary or largest. The milestone is one indicator of progress within a multi-country commercial footprint.
Understanding OncoSil™ and how it works
OncoSil™ is a single-use brachytherapy device, meaning it delivers radiation from inside the body rather than from an external source. Specifically, it places Phosphorous-32 (³²P) Microparticles directly into cancerous tissue, delivering a targeted dose of beta radiation to the tumour while limiting exposure to the surrounding critical organs.
This targeted approach is clinically significant given the anatomy of the pancreas and bile duct, where nearby organs make precise radiation delivery particularly challenging.
Peer-reviewed histopathological analysis confirmed zero migration of microparticles beyond tumour tissue across all evaluated surgical specimens, a finding that directly validates the localised mechanism the device relies on to spare the surrounding organs most at risk during pancreatic tumour treatment.
Pancreatic cancer is diagnosed in approximately 500,000 people globally every year and is generally detected at a late stage, contributing to a poor prognosis for long-term survival. This widespread unmet medical need provides the context for why the 100-patient milestone in Spain carries commercial weight.
OncoSil™ has been designated as a Breakthrough Device in both Europe and the United States. In markets outside the US where the device has received regulatory approval, it is indicated for the treatment of LAPC as an adjunct to gemcitabine-based chemotherapy. In the United States, the device received approval from the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of unresectable, non-metastatic distal cholangiocarcinoma (dCCA), also as an adjunct to systemic therapy.
For readers interested in OncoSil’s regulatory progress beyond the European footprint, our full explainer on the FDA approval for distal cholangiocarcinoma covers the Humanitarian Device Exemption pathway, the estimated A$80 million US addressable market, and the post-approval study requirements the company must satisfy ahead of a full commercial launch.
Driving utilisation across an established network
Reaching 100 patients treated in Spain signals more than a numerical landmark. The company has stated that its focus is increasingly on driving utilisation across its existing 11-site network in Spain, supporting current treatment centres and broadening patient access rather than solely expanding site count.
CEO and Managing Director Nigel Lange outlined the strategic direction:
Nigel Lange, CEO & Managing Director
“Reaching our 100th patient treatment in Spain is an important milestone for OncoSil Medical and demonstrates the continued progress we are making in one of our key European markets. We are particularly encouraged by the growing engagement from clinicians and hospitals across Spain.
With 11 active treatment sites in the country, our focus is increasingly on driving utilisation across this network and ensuring that more eligible pancreatic cancer patients can access the OncoSil™ treatment.”
The milestone at Hospital HM Sanchinarro reflects the broader pattern of clinician and hospital engagement that underpins the company’s utilisation-growth strategy in Spain. Growing depth of use within the existing network, rather than purely adding new sites, represents the next operational phase the company has indicated it is pursuing. No financial projections or revenue figures were disclosed in the announcement.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving healthcare announcement the moment it drops.